

AMENDMENT TO THE CLAIMS

1-77. (Canceled)

78. (Currently amended) A method of treating a patient with breast cancer, bladder cancer or prostate cancer comprising administering to the patient an effective amount of an agent that ~~inhibits~~ binds to a peptide or polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

79. (Previously presented) The method of claim 78, wherein the agent is an antibody.

80. (Previously presented) The method of claim 79, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

81. (Previously presented) The method of claim 80, wherein the antibody is a monoclonal antibody.

82. (Previously presented) The method of claim 80 wherein the antibody is a polyclonal antibody.

83. (Currently amended) The method of claim 80, wherein the antibody is conjugated to a radionucleotide~~radionuclide~~.

84. (Previously presented) The method of claim 80, wherein the antibody is linked to a chemotherapeutic agent.

85. (Canceled) ~~The method of claim 78, wherein the cancer is bladder cancer, breast cancer or prostate cancer.~~

86. (Currently amended) The method of claim 78, wherein the agent inhibits binds to a polypeptide encoded by SEQ ID NO: 3, SEQ ID NO: 83 or SEQ ID NO: 85 or a fragment thereof.

87. (Currently amended) A method of treating a breast cancer, bladder cancer or prostate cancer cell comprising administering to the cell an effective amount of an agent that inhibits binds to a peptide or polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

88. (Previously presented) The method of claim 87, wherein the agent is an antibody.

89. (Previously presented) The method of claim 88, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

90. (Previously presented) The method of claim 88, wherein the antibody is a monoclonal antibody.

91. (Previously presented) The method of claim 88, wherein the antibody is a polyclonal antibody.

92. (Currently amended) The method of claim 88, wherein the antibody is conjugated to a radionucleotide radionuclide.

93. (Previously presented) The method of claim 88, wherein the antibody is linked to a chemotherapeutic agent.

94. (Previously presented) The method of claim 87, wherein the cell is in a patient.